ONC206 in Oncology

ONC206 acts as a DRD2 antagonist and ClpP agonist that exhibits enhanced non-competitive effects, high specificity, nanomolar potency, and disruption of DRD2 homodimers. ONC206 has highly potent activity in preclinical models of difficult-to-treat neuroendocrine tumors and high-grade gliomas. Downstream of target engagement, ONC206 exhibits a mechanism of action similar to that of ONC201, involving activation of the integrated stress response and induction of TRAIL.

For more information on ONC206, please refer to our Publications and to the ‘Our Science’ section of our website.

Development of ONC206

The FDA accepted an IND for ONC206 in 2019 and ONC206 is currently in the clinical development phase. A Phase I trial, led by researchers at the NIH, is expected to start in the first half of 2020.

In 2018, Oncoceutics and Calvert Research announced that the two companies have entered into a product development and investment partnership agreement to further develop ONC206. Calvert Research will enlist the capabilities of its CRO affiliate, Calvert Laboratories, Inc. to conduct safety and pharmacology studies on ONC206.

The United States Patent and Trademark Office (USPTO) has issued a patent providing the company with composition of matter protection for ONC206.